All posts by admin

Veradigm^® India Private Limited, the India subsidiary of Veradigm (OTCMKTS: MDRX), a US-based leader in clinical and revenue cycle solutions for independent practices, today announced a major expansion of its Pune operations, doubling its office capacity and adding a new managing director. This milestone marks a significant chapter in Veradigm’s growth journey, reflecting the company’s continued investment in its people, its infrastructure, and its long-term vision for India.

Located in one of Pune’s prime business districts, the expansion is designed to support scale, inspire collaboration, and create an environment where teams can do their best work. It is a direct expression of Veradigm’s future-ready workplace vision.

A Future-Ready Workplace

Veradigm’s Pune expansion features:

• Large seating capacity to support rapidly growing teams, with the newly added floor almost doubling our total Pune office capacity across two floors.
• Greenscape elements that bring openness, energy, and balance into the workspace, supporting employee wellbeing and focus.
• Informal and collaborative areas designed to encourage connection, creativity, and agile ways of working across teams.

“One of the key levers of our growth strategy is an AI-fueled global workforce,” said Tally Baker, Chief Human Resource Officer, of Veradigm. “Veradigm’s Pune-based workforce is a pivotal part of a 24-by-7 focus on delivering outcomes that matter for our clients.”

New Leadership to Drive India Strategy

To lead this next chapter of growth, Veradigm announced the appointment of Divesh Singla as Managing Director, India Operations. In this role, Divesh will be responsible for accelerating Veradigm’s India strategy, scaling the Pune team, deepening technology and delivery capabilities, and positioning India as a core engine of the company’s global operations. He brings 20+ years of experience running global operations across India and South-east Asia, with a track record of building high-performing, inclusive teams.

“I am energized to join Veradigm at such a pivotal moment. India is a strategic growth market, and this expansion reflects the organization’s conviction in what our team here can achieve. My focus will be on scaling our talent, strengthening our technology capabilities, and making Pune a place where the best people in this industry want to build their careers,” said Mr. Singla.

Built Through Collaboration, Guided by Values

This achievement was made possible through strong leadership, cross-functional collaboration, thoughtful planning, and a shared focus on delivering spaces aligned with Veradigm’s values and standards. The facility features modern infrastructure, flexible workspaces, and employee-centric amenities aimed at supporting a dynamic and growing workforce.

As we look ahead, Veradigm remains committed to building workplaces that grow with its business and empower people to do their best work.

Pune: A Strategic Hub for Technology and Talent

Long recognized as India’s educational hub, Pune has emerged as a premier destination for businesses, offering a robust ecosystem and a deep pool of skilled professionals. By strengthening its presence in the city, Veradigm aims to tap into this rich talent base and further grow its capabilities in technology development and customer support, reinforcing Pune’s role as a critical pillar in Veradigm’s global strategy.

About Veradigm®

Veradigm has a proven history of delivering clinical and revenue cycle solutions that help independent practices improve outcomes and financial performance. Our AI-forward data and technology also help over 20,000 provider practices connect with health plans and biopharma to eliminate inefficiencies, close care gaps, and create a more affordable health system.

© 2026 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427265241/en/

• Strategic collaboration to co-develop advanced digital and engineering solutions in robotics, IoT, and cybersecurity
• Partnership to combine UST’s engineering and AI capabilities with iHUB’s research and innovation ecosystem

UST, a leading AI and technology transformation solutions company, has signed a Memorandum of Understanding (MoU) with iHUB DivyaSampark, the technology innovation hub at IIT Roorkee and a joint initiative of the Department of Science and Technology (DST), Government of India, to accelerate the development in engineering R&D and deep‑tech innovation.

By combining UST’s expertise in embedded hardware, firmware engineering, cloud platforms, and AI/ML and data science with iHUB DivyaSampark’s strong research, innovation, and startup ecosystem, the partnership aims to create scalable, high-impact solutions.

As part of the collaboration, both organizations will jointly work on next-generation technologies and solutions across critical domains, including cyber-physical systems, advanced digital engineering, and AI-driven applications. The partnership will also enable the development of customized solutions designed to meet operational and on-ground requirements for clients in India. Additionally, the collaboration will facilitate joint research and development, technology transfer, and commercialization of solutions to drive real-world impact.

Speaking on the partnership, Alexander Varghese, President, UST, said, “This collaboration represents a pivotal step in advancing engineering R&D and deep-tech innovation in India. By combining UST’s deep engineering expertise and AI-led capabilities with iHUB’s strong research foundation, we are creating a powerful platform to co-develop solutions that address complex, real-world challenges. Together, we aim to accelerate innovation and deliver scalable, high-impact solutions that drive meaningful and lasting change.”

Manish Anand, Chief Executive Officer, iHUB-IIT Roorkee, added, “We are pleased to partner with UST in a collaboration that brings together academia, research, and industry to address critical challenges in the business. Leveraging iHUB DivyaSampark’s focus on cyber-physical systems and innovation, along with UST’s global technology expertise, this partnership will enable the development of advanced, application-oriented solutions. We believe this collaboration will play a key role in strengthening India’s technology ecosystem while fostering innovation and capability development.”

This collaboration underscores UST’s commitment to driving innovation through strategic partnerships that bridge academia, research, and industry. Prior to this, UST has signed MoUs in the past with notable institutions, namely BITS Pilani, IIT Madras, Western Sydney University, and T-Works. By leveraging its global expertise in digital engineering and AI, UST continues to play a key role in advancing next-generation solutions that address complex, real-world challenges across critical sectors.

The MoU was formally exchanged at UST Thiruvananthapuram campus between Manish Anand, CEO, iHUB-IIT Roorkee, and Dileep Sivan Pillai, Vice President & Head of India Business, UST, in the presence of senior leaders from both organizations. Wg Cdr MS Mathew, Advisor, iHUB, represented IIT Roorkee, while Varghese Cherian, Head, Technology Services; Ashok G. Nair, Sr. Director & Head, UST Innovation Labs; Bhavesh Sasirajan, Head of Partnerships & Alliances – US & APAC; Nikitha Nath Bahadur, Strategic Partnerships & Program Management; Vigil Nair, Director, Workplace Management, and Roshni Das, Senior Lead – PR & Marketing – Kerala; Ramesh Ramakrishnan, Lead – Product Engineering; Abhilash Krishnan, Delivery Manager – Engineering Solutions; Anoop Nair, Delivery Manager – Engineering; from UST, attended the MoU exchange ceremony.

Microsoft and Postel, a Poste Italiane Group company, announce an evolution of their collaboration and of the agreements they have signed for the digitalization of Italian businesses, welcoming Audiencerate as technology partner in the Data and Direct & Digital Marketing space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427013396/en/

The Marketing Data Platform combines AI-powered market intelligence, first-party data and omnichannel activation to help SMEs analyze market trends and historical campaign performance, turning insights into audiences and increasingly targeted future actions.

The agreement provides for the distribution of an integrated platform that combines Postel’s omnichannel physical-and-digital communication capabilities with Audiencerate’sdata intelligence functionalities and Microsoft’s AI and Cloud solutions.

The solution enables SMEs to leverage and activate their own data across the entire customer relationship lifecycle, automating and orchestrating omnichannel communication campaigns. Thanks to the market-analysis capabilities built into the platform, businesses will be able to access competitive insights and real-time sector trends, turning data into a concrete strategic advantage.

Audiencerate is a global partner of the Microsoft AI Cloud Partner Program and integrates Azure AI capabilities into its own data management and activation infrastructure, making tools that were previously reserved for large enterprises accessible to SMEs as well.

“With this partnership we place data at the heart of the growth strategy of Italian SMEs, offering them AI and digital marketing tools that until today were the exclusive preserve of the major players,” said Gianluca Leotta, President of Audiencerate.

“The Cloud makes innovation more accessible, and Artificial Intelligence can enable even smaller organizations to manage their processes more intelligently, regaining competitiveness,” said Annamaria Bottero, Global Partner Solutions Lead at Microsoft Italy.

The platform, already available with a complete suite for customer segmentation, market intelligence, and connectors for Postel’s Physical and Digital communication channels, will be further enriched in the coming weeks with a marketing automation module and the introduction of additional communication channels.

The solution will also continue to evolve over time thanks to Microsoft’s AI innovations, natively available within the platform, and to Audiencerate’s global partnerships in the AdTech and MarTech ecosystems, delivering Italian SMEs a continuous competitive advantage.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427013396/en/

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of its BlueVerse Studio in Bengaluru, a hub designed to accelerate Enterprise Agentic AI adoption for clients and deliver measurable business outcomes. LTM continues to launch more studios globally to drive AI innovation and also has studios in London and Mumbai.

As part of the company’s ongoing investment in bringing innovation closer to clients, the BlueVerse Studio was created to help clients scale AI solutions from experiments to practical applications while ensuring trust and control. It unites LTM’s strongest AI capabilities, including BlueVerse CraftStudio, physical AI showcases, and industry-centric AI offerings, within one ecosystem along with:

• Multiple BlueVerse-certified consulting and delivery professionals currently support enterprise-grade AI solutions. These certifications provide expertise in developing intelligent agents and managing unified AI platforms, ensuring secure and impactful business outcomes. 
• A constantly growing number of digital employees, spanning an expanding range of roles
• BlueVerse research scientists with a growing portfolio of foundational patents
• BlueVerse SkillSphere, a unified AI platform for hyper-personalized learning and talent transformation – offers customized learning and certification paths for different organizational roles. It features gamified recognition, community engagement, and advanced programs through partnerships with institutions like IIT Kharagpur and MIT Open Learning (via upGrad).
• BlueVerse SkilletWeave, a marketplace with hundreds of domain skills

The BlueVerse Studio helps organisations run separate agentic AI pilots with clear plans for scaling, governance, and ROI. It provides a framework with rapid prototyping, reusable components, and Responsible AI controls. It provides ready-to-use workflows that demonstrate end-to-end transformation and multi-agent collaboration using client data and KPIs. LTM brings together the very best of human insights and intelligent systems. As a holistic ecosystem, BlueVerse Studio offers clients a tangible and experiential view of AI in action.

“The BlueVerse ecosystem is central to our vision to be our clients’ gateway to the agentic enterprise era. More than a showcase of technology, BlueVerse Studio is a collaborative space where our best ideas are tested, solutions are accelerated, and clients gain the confidence to scale AI responsibly in the agentic enterprise era,” said Venu Lambu, Chief Executive Officer and Managing Director, LTM.

With LTM’s pivot to becoming an AI-centric organization, the company has built demonstrable AI capabilities and compelling client success stories while simultaneously focusing on internal adoption, research leadership, and superior talent readiness and is poised to help its clients Outcreate in the new agentic enterprise era.

FPT and Intel, a global leader in semiconductor and AI technologies, announced a strategic relationship to deliver an end-to-end AI-driven factory optimization solution. Powered by AI, simulation, and digital manufacturing technologies, the collaboration aims to reduce bottlenecks, accelerate decision-making and improve downtime recovery, facilitating the sector’s transition towards AI-driven, autonomous operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427301486/en/

Intel and FPT collaborate to advance AI-driven autonomous factories with digital manufacturing platforms

As manufacturers increasingly face complex, data-intensive operations, many still struggle to predict disruptions, optimize production flows, and fully leverage real-time data. This relationship addresses these challenges by enabling closed-loop factory intelligence—where simulation, real-time data, and AI continuously optimize performance.

The collaboration brings together Intel’s high-speed simulation and digital twin technology with FPT’s data platforms and system integration expertise. Intel® Automated Factory Solutions (AFS)—including Intel® Factory Pathfinder and Intel® Factory Recon—allow manufacturers to gain a dynamic, end-to-end view of factory operations. FPT complements these capabilities with its digital manufacturing platforms, FleziOps (MOM+), FleziQMS (Quality Management Suite), and FleziUDP (Unified Data Platform), which integrate data across MES, ERP, and shop-floor systems to create a unified operational data layer. This foundation enables seamless deployment of Intel’s AI-driven optimization tools within live production environments.

Together, the solution allows manufacturers to:

• Run thousands of AI-driven simulations to identify optimal production strategies
• Detect and resolve bottlenecks before they impact production
• Improve scheduling and material flow across complex production lines
• Visualize and analyze factory operations through real-time digital twins

Paul Schneider, Principal Engineer and Director at Intel Corporation, said: “Manufacturing is one of the most complex environments in the world, and optimizing it requires more than isolated tools; it requires a connected, intelligent system. By collaborating with FPT, we’re able to extend the reach of Intel’s factory optimization technologies and help manufacturers operationalize AI-driven insights at scale.”

“Manufacturing has reached a turning point where AI is not just augmenting operations but actively orchestrating them. At FPT, we see a growing demand for smarter, more adaptive manufacturing systems that can respond to real-time conditions,” added Hoan Nguyen, FPT Software SEVP and FPT Americas CEO, FPT Corporation. “By combining Intel’s expertise with our AI-first solutions and global delivery capability, we are helping manufacturers achieve new levels of operational agility and efficiency.”

FPT has deployed digital transformation projects to more than 150 companies in manufacturing to convert production lines into smart factories with enhanced supply chain resilience. This expertise is backed by end-to-end AI-enabled solutions delivered by an AI-augmented workforce of over 25,000 globally certified engineers. Through its global delivery model across more than 30 countries and territories, FPT enables companies to scale these outcomes across their operations worldwide, thereby enhancing time to value and cost efficiency.

About FPT

FPT Corporation (FPT) is a globally leading Vietnam-headquartered technology and IT services provider, with operations spanning more than 30 countries and territories. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. FPT focuses on three critical transformations: Digital Transformation, Intelligence Transformation, and Green Transformation. In 2025, FPT reported a total revenue of USD 2.66 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT’s global IT services, please visit https://fptsoftware.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427301486/en/

HDFC securities, one of India’s leading stockbroking firms, today announced the integration of its new commodity derivatives trading feature on the InvestRight app. This development offers investors a unified and seamless way to participate in the commodities market alongside equities and other asset classes, reinforcing HDFC securities’ commitment to providing an integrated and smarter investing experience.

The integration of Commodity Derivatives on the InvestRight app was jointly launched by Ms. Praveena Rai, MD & CEO of MCX, and Mr. Dhiraj Relli, MD & CEO of HDFC securities. This collaboration underscores the industry’s ongoing efforts to enhance accessibility, simplify trading, and promote informed investment decisions. With this rollout, HDFC securities’ customers can now trade across MCX-listed commodities, including bullion, metals, energy, agricultural products and indices such as Bulldex, directly within the existing InvestRight app, ensuring a smooth and comprehensive trading experience.

Commenting on the launch, Ms Praveena Rai, MD & CEO, Multi Commodity Exchange of India, said, “The rapidly increasing growth and diversification of India’s commodity derivatives market highlight its increasing significance within the broader financial ecosystem. With diverse participation driving this momentum, we believe that leveraging modern, technology-driven applications is essential for investors to capitalize on these opportunities and contribute to India’s evolving investment landscape.”

Reacting to the development, Mr Dhiraj Relli, MD & CEO of HDFC securities, said, “Our goal is to make commodity trading more accessible, integrated, and efficient. Furthermore, our seamless application, backed by strong research and educational support, empowers our customers to confidently navigate commodity markets. Through this integration with MCX, we are committed to providing a secure, user-friendly experience that drives smarter investing in India’s growing commodity landscape, ultimately Powering India’s Investments.”

Discover the Key Features of Our New Commodity Derivatives Offering:

Collateral Pledge Limits for Traders: Customers can pledge eligible securities from their existing portfolios to receive margin for trading. This collateral margin system operates similarly to conventional F&O trading using pledged margin, enabling traders to unlock trading capacity without having to block 100% of their cash capital. The pledged securities are managed with standards that ensure robust risk management aligned with exchange norms.

Advanced Trading Tools and Features: The app offers a comprehensive suite of analytical and execution tools, including real-time charts, option chains, research insights, instant order placement, modification, cancellation, and live tracking of positions. Customers can efficiently manage multiple positions with ease, enhancing their overall trading experience.

Direct Fund Management for Seamless Trading: HDFC Bank account holders benefit from the convenience of not having to transfer funds to a separate trading account, as the system is designed to hold the required funds directly. This seamless integration simplifies trading in this new segment, making the process more efficient and hassle-free.

Research and Support to Empower Traders: Users will have access to exclusive research content on commodities, including daily and weekly market reports, technical analysis, and intraday and positional derivative calls. To support new participants, HDFC securities is also developing educational videos, blogs, and conducting live webinars with Q&A sessions to foster learning and confidence.

The commodity derivatives offering with this launch will go live on the InvestRight app, besides being already live on HDFC SKY, the discount broking platform. The offering is slated to launch soon on the web version of InvestRight, providing clients with multiple channels to access and trade commodities.

As HDFC securities continues to innovate and expand its offerings, this new offering underscores the firm’s dedication to empowering investors with comprehensive, secure, and user-friendly trading solutions driving smarter investments across India’s dynamic commodity markets.

Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle.

As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Lithium-ion chemistry presents inherent challenges, including flammability and reliance on constrained global supply chains—issues that become more acute in large-scale energy storage, where higher energy densities considerably increase fire risks, and growing demand across sectors further strains the supply chain and imperils energy sovereignty.

At the same time, the pace of innovation must accelerate because existing battery solutions are not designed to meet the cost, safety, and performance required for today’s infrastructure demands, particularly in urban areas. Permitting restrictions due to fire risks and long delays are the top concerns for energy storage system project developers.

Alsym’s physics-informed AI platform is designed to accelerate battery innovation by fundamentally improving how new chemistries are discovered, developed, and scaled:

• Uses physics-guided AI to narrow an otherwise unmanageable range of possible battery chemistries — rapidly converges on deployable, non-flammable, high-performance battery chemistries rather than exploring candidates in isolation.
• Integrates machine learning with automated, closed-loop experimentation to extract maximum actionable learning from each test, accelerating progress across materials, cell design, and operating conditions beyond traditional trial-and-error approaches.
• Applies continuous electrochemical, materials, and molecular diagnostics and feedback to understand not just how a battery performs, but why—enabling targeted optimization and robust, predictable scaling from lab to prototype to pilot and commercial production.
• Drives AI-optimized system-level end-to-end co-design of materials, cell architecture, and manufacturing processes – ensuring performance, safety, cost and manufacturability are achieved simultaneously at scale.

This innovation platform approach underpins the development of Alsym’s Na-Series and positions the company to rapidly deliver continued innovation as it scales.

The rapid development of Alsym’s Na-Series sodium-ion battery utilized a chemistry that was identified, tested, developed and built in under a year. Na-Series batteries are non-flammable while delivering high performance, affordability, and competitive energy density. By leveraging abundant, widely available materials, the technology also provides a secure and resilient supply chain advantage over conventional lithium-ion solutions.

“The energy transition cannot wait decades for a better answer for energy storage,” said Dr. Kripa Varanasi, Professor of Engineering at MIT and co-founder of Alsym Energy. “What’s required is a fundamentally faster way to turn innovation into infrastructure. The challenge is no longer just discovery – it’s deployment. By integrating physics-informed AI, deep electrochemical expertise, and system-level intelligence across cell architecture, operations and manufacturing, we’ve built a platform that enables continuous innovation and scalable deployment of safer, cost-effective battery technologies for critical infrastructure.”

Na-Series batteries surpass non-flammability tests

From the outset, Alsym set a clear objective: to develop a truly non-flammable and high-performance battery chemistry. The physics-informed AI platform enabled this goal—guiding the discovery and refinement of a system that eliminates the risk of thermal runaway.

Alsym has validated the inherent safety of its chemistry through rigorous testing. In accelerated rate calorimetry (ARC) testing, Na-Series cells were heated from room temperature to 400°C without ever going into thermal runaway. In nail penetration tests conducted on fully charged cells, no rupture, fire, or flame was observed at any point—demonstrating the system’s resistance to catastrophic failure modes that have challenged existing battery technologies. These results underscore the success of Alsym’s platform to deliver real innovation designed to solve a market problem.

“The safety of Na-Series enables deployments everywhere lithium-ion batteries can, and all the places lithium can’t,” said Mukesh Chatter, CEO of Alsym Energy. “The levelized cost of energy (LCOE) advantages are also clear: its wide operating temperature range enables substantial operating cost savings, and upfront costs are very competitive both at the cell and system level. Coupled with fast charge and discharge rates, and flexible use across short, medium and long durations, Alsym Na-Series is a fundamentally better battery for energy storage. For customers, this means lower total cost of ownership, reduced risk, simplified safety and thermal management requirements, broader deployment flexibility, and increased revenue through fast charge–discharge and optimized cycling that captures value from dynamic grid pricing.”

Alsym’s Na-Series batteries support a wide range of applications, including utilities and microgrids, data centers, commercial real estate, industrial operations, maritime environments, defense systems, and residential energy storage. The company is currently advancing its commercialization roadmap and will be shipping cells and modules to strategic partners starting in Q3 2026.

ABOUT ALSYM

Alsym Energy is enabling a safer, scalable energy future by rethinking battery chemistry. The company’s flagship Na-Series are non-flammable, high-performance, low cost sodium-ion batteries made with earth abundant materials. They are designed using a proprietary, physics-informed AI platform that enables the discovery of materials and commercially viable chemistries 10x faster than traditional, trial and error experiment-only methods. By combining DeepTech expertise in batteries with physics-informed AI, the platform is a closed-loop system that accelerates the entire battery development process, from ideation to manufacturing. Alsym’s Na-Series technology eliminates thermal runaway and allows energy storage to be deployed safely, and at scale, anywhere energy storage is needed — from data centers and industrial facilities to residential buildings, commercial real estate, mining, military installations or utility grids. Its wide operating temperature range avoids the need for HVAC systems for safety or performance, and fast charge and discharge rates allow multiple cycles per day, creating a powerful economic model for energy storage systems. Alsym Na-Series: A better battery for energy storage.

To learn more, visit: alsym.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427875189/en/

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427926534/en/

PCI Pharma Services announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities.

At the core of PCI’s investment plan is a $100 million project at its San Diego campus, featuring a high-speed isolator filling line for ready-to-use (RTU) prefilled syringes and cartridges. Scheduled to be operational in the first half of 2028, the line will more than double the site’s existing syringe and cartridge filling capacity. It will be PCI’s second isolator fill-finish line in San Diego, which currently supports and manufactures over 45 FDA-approved products. The campus also hosts large-scale aseptic filling for prefilled syringes and cartridges, alongside specialized capabilities in oligonucleotides, peptides, complex formulations and lyophilization for injectables such as nanoparticles, mRNA, mAbs, proteins, and highly potent products.

Meanwhile, PCI’s Bedford, New Hampshire campus is commissioning a GMP-ready bespoke isolator vial and lyophilization line that, upon commencing full-scale production this month, will be capable of producing batch sizes of up to 300,000 vials at 400 units per minute, for an annual total of 33 million – among the most robust, state-of-the-art setups of its kind in the US. The campus also will commission a customer-dedicated high-potent sterile fill-finish line slated to be one of a kind in the US.

In both San Diego and Bedford, PCI also has invested in cutting-edge automated visual inspection (AVI) systems for sterile fill-finish applications. In total, PCI’s US-based AVI infrastructure supports more than 70 million prefilled syringes and cartridges and 40 million vials per year, meeting the exacting standards of global pharmaceutical manufacturers.

Investments in Drug-Device Combination Assembly and Packaging Platforms

In partnership with leading device manufacturers, PCI has committed to numerous buildouts of autoinjector and drug-device combination assembly infrastructure at its campuses in Philadelphia, PA and Rockford, IL. Coming online via a phased approach over the next six months, the upgrades will significantly increase both capacity and scale, bolstering PCI’s integrated, clinical-through-commercial capabilities.

In 2027, PCI will add a third autoinjector line to its existing lineup, bringing its US autoinjector and device assembly capacity to more than 250 million units per year. Featuring multi-device tooling technology and flexible change parts, the company’s autoinjector lines provide comprehensive high-speed assembly, while a dedicated prefilled syringe (PFS) safety device line adds labeling and secondary packaging options.

Philadelphia and Rockford also are home to PCI’s US Packaging Centers of Excellence, which offer ample capacity for oral solid dose and injectable products, as well as substantial cold chain storage. The GMP-compliant facilities can be rapidly mobilized to support programs at clinical or commercial scale; available capacity across the two sites includes annual accommodation for 40 million blister units, 70 million bottles, and 75 million vials.

Pharmaceutical Development Centers of Excellence

In conjunction with expanding its manufacturing platform, PCI is investing in dedicated Development Centers of Excellence (CoE) in Bedford, NH and León, Spain. The CoEs will feature development capabilities spanning lyophilization, formulation, analytical support, drug-device combination assets, long-acting injectables and ophthalmic products. They will handle both highly potent and non-potent small molecule and biologic modalities in vial, prefilled syringe and cartridge presentations. The Bedford Development CoE is expected to be operational this May, with León following in June.

“The pharmaceutical industry is at an inflection point, with manufacturers seeking trusted US-based partners to provide scale, expedience, and established quality and compliance track records to support the development and commercialization of next-generation treatments,” said Salim Haffar, CEO of PCI Pharma Services. “Backed by over $1 billion in global infrastructure investment and decades of operational expertise, PCI’s multi-year journey to bolster its domestic manufacturing footprint allows us to meet growing customer demand for innovative drug product and drug delivery solutions, toward the evergreen goal of delivering life-changing therapies to patients.”

About PCI Pharma Services

PCI is a world-leading CDMO providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 38 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), and over 7,500 employees working to bring life-changing therapies to patients.

Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients’ lives. For more information, visit pci.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427926534/en/

For Trade and Medical Media Only

• The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90
• Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs)
• Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs)

Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO^® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT).

The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,¹ representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected.

The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards for fungal-free survival at Day 90, showing non-inferiority of rezafungin vs. SAR (60.7% vs. 59.0%, respectively). This demonstrates that rezafungin’s differentiated pharmacokinetics/pharmacodynamics (PK/PD) profile was comparable to the SAR in reducing the incidence of invasive fungal diseases in a high-risk patient population. Rezafungin was well tolerated, with a safety profile showing a favourable benefit/risk profile for immunocompromised patients.

The Phase III study topline results indicate comparable efficacy against invasive infections from Candida, Aspergillus and Pneumocystis in both therapeutic arms, as well as comparable mortality. In addition, results showed a favourable profile in multiple secondary endpoints, most notably treatment-emergent adverse events leading to dose-reduced interruption or withdrawal of study drug, and treatment-emergent adverse events leading to study discontinuation.

“We are very excited by the study results, which met all its endpoints, and reflect the contribution of patients enrolled across more than 50 centres in seven countries,” said Dr. Yuri Martina, Chief Development & Medical Officer at Mundipharma. “These findings represent a meaningful step forward in advancing care for this vulnerable population. Rezafungin holds the potential to change the standard of care for these patients.”

Mundipharma and its US licensee, CorMedix currently intend to target submission of a supplemental New Drug Application (sNDA) to the FDA in 2H26 based on the ReSPECT results. Mundipharma expects an EMA submission in Q3, 2026.

About rezafungin

Rezafungin is a next-generation echinocandin approved for the treatment of candidaemia and invasive candidiasis in adults.² Invasive candidiasis continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. Despite a number of available treatments, the mortality rate for patients with invasive candidiasis is as high as 40%.^3,4

Rezafunginhas been studied for the prophylaxis of invasive fungal diseases in adults undergoing allogeneic HSCT.

Approximately 1.3 million people worldwide were diagnosed with haematological malignancies in 2019,⁵ the majority of whom are at risk of treatment‑related neutropenia, leaving them highly vulnerable to invasive fungal infections and underscoring the ongoing unmet need for effective antifungal prophylaxis.

® REZZAYO is a Registered Trademark of Mundipharma, used under licence by Melinta Therapeutics LLC, a wholly owned subsidiary of CorMedix Inc. in the USA.

About Mundipharma

Mundipharma is a global healthcare company with a presence in Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East. In line with its mission, United for Patients, Mundipharma is dedicated to bringing innovative treatments to patients in the areas of pain management, infectious disease, ophthalmology, oncology, respiratory and central nervous system.

References:

1. M Quattrone et al. Managing invasive fungal infections during allogeneic hematopoietic transplantation: a 2025 update. Mediterranean Journal of Hematology and Infectious Diseases. 2025;17(1):e2025064. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12422250/ (last accessed April 2026)
2. REZZAYO^®Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/15479/smpc#gref (last accessed April 2026)
3. M Bassetti et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care. 2019;23(1):219. Available at: https://pubmed.ncbi.nlm.nih.gov/31200780/ (last accessed April 2026)
4. A Cortegiani et al. Antifungal agents for preventing fungal infections in non‑neutropenic critically ill patients. The Cochrane Database of Systematic Reviews. 2016;(1):CD004920. Available at: https://pubmed.ncbi.nlm.nih.gov/26772902/ (last accessed April 2026)
5. N Zhang et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer Journal. 2023:13(1):82. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10188596/pdf/41408_2023_Article_853.pdf (last accessed April 2026)

Job Code: GBL-S-RZF-2600002 
Date of preparation: April 2026

View source version on businesswire.com: https://www.businesswire.com/news/home/20260427620065/en/

​​​​

• Leases 6.4 msf across 86 deals in FY2026 at 17% higher leasing spreads

• Achieves double-digit growth with revenue up 13% YoY to Rs 4,582 crores and Net Operating Income up 15% YoY to Rs 3,760 crores; Distributions at Rs 2,396 crores (Rs 25.28 per unit), up 10% YoY

• Delivers record 3.3 msf of new office developments in FY2026 in Bengaluru and Chennai

• Provides FY2027 guidance with distributions in the range of Rs 27.00 to Rs 28.60 per unit, implying a 10% YoY growth in distributions at midpoint and occupancy in the range of 95%-96% by value

• Portfolio valuation strengthened, with GAV up 15% YoY to Rs 70,540 crores and NAV up 16% YoY to Rs 491.62 per unit

• Launch of a 518-key, two Hilton-branded Hotels at Embassy TechVillage in Bengaluru, with phased openings from Jul’26 to Mar’27

Embassy Office Parks REIT (NSE: EMBASSY / BSE: 542602) (‘Embassy REIT’), India’s first listed REIT and the largest office REIT in Asia by area, reported results today for the fourth quarter and full year ended March 31, 2026. 

Amit Shetty, Chief Executive Officer of Embassy REIT, said,

“FY2026 was another exceptional year for Embassy REIT. We delivered 6.4 msf of leasing and double-digit growth across revenue, NOI and distributions, driven by strong GCC-led demand, with Chennai emerging as a key growth driver. We delivered a record 3.3 msf of new office space, scaled redevelopment and strengthened our balance sheet through efficient capital raises, including pioneering the first-ever 10-year NCD issuance in India’s REIT market. We are guiding for double-digit growth in both distributions and NOI again in FY2027 and remain well-positioned to deliver sustained long-term value for our unitholders.”

The Board of Directors of Embassy Office Parks Management Services Private Limited (‘EOPMSPL’), Manager to Embassy REIT, at its Board Meeting held earlier today, declared a distribution of Rs 616 crores or Rs 6.50 per unit for Q4 FY2026. With this, the cumulative distribution for FY2026 totals Rs 2,396 crores or Rs 25.28 per unit. The record date for the Q4 FY2026 distribution is April 30, 2026, and the distribution will be paid on or before May 08, 2026. 

Business Highlights

• Leased 6.4 msf in FY2026 across 86 deals at 17% higher leasing spreads, including 4.0 msf of new leasing, 1.5 msf of renewals, and 0.9 msf of pre-leases

• Chennai saw strong momentum with robust leasing from large global companies – highlighted by one of the city’s largest deals – a full 0.65 msf block taken for a leading US GCC

• GCCs accounted for ~60% of the annual leasing activity, led by demand from Technology, Healthcare & BFSI sectors

• Portfolio occupancy increased by 300 bps to 94% (by value*) in FY2026

Financial Highlights

• Grew Revenue from Operations by 13% YoY to Rs 4,582 crores and Net Operating Income (NOI) by 15% to Rs 3,760 crores in FY2026

• Delivered Distributions of Rs 2,396 crores or Rs 25.28 per unit, up 10% YoY for FY2026; Cumulative distributions of over Rs 14,400 crores since listing

• Raised Rs 11,200 crores in FY2026, including Rs 3,400 crores of 10-year NCDs, lowering the in-place cost of debt by 65 bps to 7.25%

• Portfolio GAV grew by 15% YoY to Rs 70,540 crores and NAV by 16% YoY to Rs 491.62 per unit

Operational & Growth Highlights

• Delivered a record 3.3 msf of new office space this year and acquired a 0.3 msf marquee asset in Embassy GolfLinks

• Scaled up redevelopment project at Embassy Manyata to 1.4 msf (vs. 0.8 msf earlier); expected yield of 22%

• Total development pipeline of 6.2 msf with a Rs 3,500 crore capital outlay expected to deliver ~ Rs 610 crores in stabilized NOI by FY2030

• Actively evaluating ~12.6 msf of potential acquisition opportunities from both Embassy Group and third parties

• Hotel portfolio performed well with 63% occupancy and 8% ADR growth YoY. Advancing a 518-key dual-branded Hilton development at Embassy TechVillage with 211-key Hilton Garden Inn expected to launch in Jul’26

• Unitholder register expanded to over 135,000, up from 4,000 at IPO, with a marked rise in domestic retail participation; delivered ~22% total returns in FY2026

Investor Materials and Quarterly Investor Call Details

Embassy REIT has released a package of information on the quarterly results and performance, that includes (i) audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, (ii) an earnings presentation covering Q4 FY2026 and FY2026 results, and (iii) supplemental operating and financial data book that conforms with leading reporting practices across global REITs. All these materials are available in the Investors section of our website at www.embassyofficeparks.com.

Embassy REIT will host a conference call on April 27, 2026 at 17.00 hours Indian Standard Time to discuss the Q4 FY2026 results and full year FY2026 results. A replay of the call will be available in the Investors section of our website at www.embassyofficeparks.com.